P60 Efficacy of switching to infliximab biosimilar (Remsima®) in paediatric inflammatory bowel disease (PIBD): a 2-Year retrospective evaluation | Archives of Disease in Childhood

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via RCPCH

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Citation Tools

Abstracts from the Neonatal and Paediatric Pharmacists Conference November 2019

Sutton Coldfield, UK

P60 Efficacy of switching to infliximab biosimilar (Remsima®) in paediatric inflammatory bowel disease (PIBD): a 2-Year retrospective evaluation

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Yaqub F, Crook J, Fell J

P60 Efficacy of switching to infliximab biosimilar (Remsima®) in paediatric inflammatory bowel disease (PIBD): a 2-Year retrospective evaluation

Archives of Disease in Childhood 2020;105:e37-e38.